WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318671
CAS#: 155213-67-5
Description: Ritonavir is an inhibitor of HIV-1 protease used to treat HIV infection and AIDS. It is widely used as a booster of other protease inhibitors. More specifically, ritonavir is used to inhibit a particular liver enzyme that normally metabolizes protease inhibitors, CYP3A4.
Hodoodo Cat#: H318671
Name: Ritonavir
CAS#: 155213-67-5
Chemical Formula: C37H48N6O5S2
Exact Mass: 720.31
Molecular Weight: 720.940
Elemental Analysis: C, 61.64; H, 6.71; N, 11.66; O, 11.10; S, 8.90
Synonym: Ritonavir; Norvir; ABT-538; A-84538; Norvir Sec; 538, ABT; ABT 538; ABT-538; ABT538;
IUPAC/Chemical Name: 1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
InChi Key: NCDNCNXCDXHOMX-UHFFFAOYSA-N
InChi Code: InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)
SMILES Code: CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Ritonavir is a HIV protease inhibitor and a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM. |
| In vitro activity: | Stimuli-sensitive nanomicelles along with hyaluronic acid targeting and ritonavir addition can effectively serve as a chemotherapeutic drug delivery agent for metastatic breast cancer and triple-negative breast cancer. Reference: Int J Mol Sci. 2021 Jan 27;22(3):1257. https://pubmed.ncbi.nlm.nih.gov/33513992/ |
| In vivo activity: | Nirmatrelvir plus ritonavir reduced the overall risk for hospitalization or death after an outpatient diagnosis of COVID-19. Recipients of nirmatrelvir plus ritonavir had lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]). Reference: Ann Intern Med. 2023 Jan;176(1):77-84. https://pubmed.ncbi.nlm.nih.gov/36508742/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 10.0 | 13.90 |
The following data is based on the product molecular weight 720.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Gote V, Sharma AD, Pal D. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2021 Jan 27;22(3):1257. doi: 10.3390/ijms22031257. PMID: 33513992; PMCID: PMC7865449. 2. Marima R, Hull R, Dlamini Z, Penny C. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec;132:110829. doi: 10.1016/j.biopha.2020.110829. Epub 2020 Oct 12. PMID: 33059259. 3. Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023 Jun;162:114636. doi: 10.1016/j.biopha.2023.114636. Epub 2023 Apr 1. PMID: 37004323; PMCID: PMC10065864. 4. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13. PMID: 36508742; PMCID: PMC9753458. |
| In vitro protocol: | 1. Gote V, Sharma AD, Pal D. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2021 Jan 27;22(3):1257. doi: 10.3390/ijms22031257. PMID: 33513992; PMCID: PMC7865449. 2. Marima R, Hull R, Dlamini Z, Penny C. The dual protease inhibitor lopinavir/ritonavir (LPV/r) exerts genotoxic stress on lung cells. Biomed Pharmacother. 2020 Dec;132:110829. doi: 10.1016/j.biopha.2020.110829. Epub 2020 Oct 12. PMID: 33059259. |
| In vivo protocol: | 1. Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023 Jun;162:114636. doi: 10.1016/j.biopha.2023.114636. Epub 2023 Apr 1. PMID: 37004323; PMCID: PMC10065864. 2. Dryden-Peterson S, Kim A, Kim AY, Caniglia EC, Lennes IT, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med. 2023 Jan;176(1):77-84. doi: 10.7326/M22-2141. Epub 2022 Dec 13. PMID: 36508742; PMCID: PMC9753458. |
1: Rojas J, Lonca M, Imaz A, Estrada V, Asensi V, Miralles C, Domingo P, Montero
M, Del Rio L, Fontdevila J, Perez I, Cruceta A, Gatell JM, Arnedo M, Martínez E.
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
HIV Med. 2016 May;17(5):340-9. doi: 10.1111/hiv.12314. Epub 2015 Sep 10. PubMed
PMID: 27089862.
2: Yang W, Xiao Q, Wang D, Yao C, Yang J. Evaluation of pharmacokinetic
interactions between long-acting HIV-1 fusion inhibitor albuvirtide and
lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and
simulation results. Xenobiotica. 2016 Apr 6:1-11. [Epub ahead of print] PubMed
PMID: 27052428.
3: Shiffman ML, Rustgi V, Bennett M, Forns X, Asselah T, Planas Vila R, Liu L,
Pedrosa M, Moller J, Reau N. Safety and Efficacy of
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in
HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J
Gastroenterol. 2016 Apr 5. doi: 10.1038/ajg.2016.108. [Epub ahead of print]
PubMed PMID: 27045929.
4: Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E,
Maartens G. Drug-drug interactions between bedaquiline and the antiretrovirals
lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant
TB. J Antimicrob Chemother. 2016 Apr;71(4):1037-40. doi: 10.1093/jac/dkv447. Epub
2016 Jan 7. PubMed PMID: 26747099.
5: Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics
and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C
virus treatment, with and without ritonavir in healthy volunteers. Br J Clin
Pharmacol. 2016 May;81(5):929-40. doi: 10.1111/bcp.12873. Epub 2016 Feb 24.
PubMed PMID: 26710243.
6: Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H,
Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L,
Wittkop L, Calvez V, Marcelin AG, Raffi F; NEAT 001/ANRS 143 Study Group.
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial:
raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus
darunavir/ritonavir as first-line ART. J Antimicrob Chemother. 2016
Apr;71(4):1056-62. doi: 10.1093/jac/dkv427. Epub 2015 Dec 24. PubMed PMID:
26702926.
7: Lee FJ, Marriott D, Bloch M, Richardson R, Mackenzie N, Carr A. Post-prandial
lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults
commencing combination ART. J Antimicrob Chemother. 2016 Apr;71(4):1127-9. doi:
10.1093/jac/dkv436. Epub 2015 Dec 18. PubMed PMID: 26682962.
8: Borges ÁH, Lundh A, Tendal B, Bartlett JA, Clumeck N, Costagliola D, Daar ES,
Echeverría P, Gisslén M, Huedo-Medina TB, Hughes MD, Huppler Hullsiek K, Khabo P,
Komati S, Kumar P, Lockman S, MacArthur RD, Maggiolo F, Matteelli A, Miro JM, Oka
S, Petoumenos K, Puls RL, Riddler SA, Sax PE, Sierra-Madero J, Torti C, Lundgren
JD. Non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted
protease inhibitor-based regimens for initial treatment of HIV infection: a
systematic review and meta-analysis of randomised trials. Clin Infect Dis. 2016
Apr 18. pii: ciw236. [Epub ahead of print] PubMed PMID: 27090986.
9: Slama L, Landman R, Assoumou L, Benalycherif A, Samri A, Joly V, Pialoux G,
Valin N, Cabié A, Duvivier C, Lambert-Niclot S, Marcelin AG, Peytavin G,
Costagliola D, Girard PM; IMEA 040 DATA Study Group. Efficacy and safety of
once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual
nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive
patients with severe immunosuppression: a 48 week, non-comparative, randomized,
multicentre trial (IMEA 040 DATA trial). J Antimicrob Chemother. 2016 Apr 10.
pii: dkw103. [Epub ahead of print] PubMed PMID: 27068399.
10: Łucejko M, Parfieniuk-Kowerda A, Flisiak R. Ombitasvir/paritaprevir/ritonavir
plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opin
Pharmacother. 2016 Apr 11. [Epub ahead of print] PubMed PMID: 27064432.
11: Gane EJ, Rouzier R, Hassanein T, Stedman CA, Mazur W, Kupcova V, Le Pogam S,
Eng S, Voulgari A, Morcos PN, Brennan BJ, Scalori A, Thommes J. Ritonavir-boosted
danoprevir-based regimens in treatment-naive and prior null responders with HCV
genotype 1 or 4 and compensated cirrhosis. Hepatol Int. 2016 May;10(3):478-87.
doi: 10.1007/s12072-015-9699-9. Epub 2016 Feb 17. PubMed PMID: 26886127.
12: LaFountaine JS, Jermain SV, Prasad LK, Brough C, Miller DA, Lubda D, McGinity
JW, Williams RO 3rd. Enabling thermal processing of ritonavir-polyvinyl alcohol
amorphous solid dispersions by KinetiSol® Dispersing. Eur J Pharm Biopharm. 2016
Apr;101:72-81. doi: 10.1016/j.ejpb.2016.01.018. Epub 2016 Feb 6. PubMed PMID:
26861929.
13: Calderón MM, Penzak SR, Pau AK, Kumar P, McManus M, Alfaro RM, Kovacs JA.
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone
Concentrations in HIV-Infected Subjects. Clin Infect Dis. 2016 Apr
15;62(8):1036-42. doi: 10.1093/cid/ciw028. Epub 2016 Jan 20. PubMed PMID:
26797214; PubMed Central PMCID: PMC4803107.
14: Khatri A, Dutta S, Wang H, Podsadecki T, Trinh R, Awni W, Menon R. Evaluation
of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir,
Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clin Infect
Dis. 2016 Apr 15;62(8):972-9. doi: 10.1093/cid/civ1213. Epub 2016 Jan 5. PubMed
PMID: 26740513.
15: Dickinson L, Winston A, Boffito M, Khoo S, Back D, Siccardi M. Simulation of
the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and
dose adjustment strategies: a population pharmacokinetic approach. J Antimicrob
Chemother. 2016 Apr;71(4):1041-5. doi: 10.1093/jac/dkv439. Epub 2015 Dec 27.
PubMed PMID: 26712906.
16: Saab S, Gonzalez YS, Huber C, Wang A, Juday T. Cost-effectiveness of
Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver
Transplant Recurrent Genotype 1 HCV. Liver Int. 2016 Apr;36(4):515-21. doi:
10.1111/liv.13033. Epub 2015 Dec 25. PubMed PMID: 26610059.
17: van Lunzen J, Pozniak A, Gatell JM, Antinori A, Klauck I, Serrano O, Baakili
A, Osiyemi O, Sevinsky H, Girard PM. Brief Report: Switch to Ritonavir-Boosted
Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1
Infection: A Randomized Pilot Study. J Acquir Immune Defic Syndr. 2016 Apr
15;71(5):538-43. doi: 10.1097/QAI.0000000000000904. PubMed PMID: 26605505; PubMed
Central PMCID: PMC4804741.
18: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M,
Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA,
Gatell JM, García F; MARAVIPEP Study Group. A randomized clinical trial comparing
ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus
emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob
Chemother. 2016 Mar 18. pii: dkw048. [Epub ahead of print] PubMed PMID: 26994091.
19: Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M,
Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA,
Gatell JM, García F; RALPEP Study Group. A randomized clinical trial comparing
ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus
emtricitabine for post-exposure prophylaxis for HIV infection. J Antimicrob
Chemother. 2016 Mar 18. pii: dkw049. [Epub ahead of print] PubMed PMID: 26994089.
20: Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H,
Brennan BJ, Zhou J, Le Pogam S, Najera I, Thommes JA, Hill G. Ritonavir-boosted
danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C
patients with or without cirrhosis. J Gastroenterol Hepatol. 2016 Mar 19. doi:
10.1111/jgh.13374. [Epub ahead of print] PubMed PMID: 26992248.
